Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility

VANCOUVER, British Columbia, April 28, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it will be inaugurating its recently completed psilocybin cultivation facility with a grand opening event and reception for members of the media, investors and other stakeholders relevant to the Company’s developing position as a leading supplier in the field of psychedelic and functional mushrooms on Friday, May 27th, 2022.

The executive team and advisory board will be welcoming guests and dignitaries from the psychedelic business space, the medical and public health fields, local and national politics, and the Indigenous community to celebrate this significant achievement. Renowned psychedelics industry journalist and author will act as Master of Ceremonies.

Committed to showcasing a world-class GMP-grade cultivation facility for mushroom enthusiasts, Optimi plans to livestream the event on Instagram for guests unable to attend.

Media outlets, psychedelic science enthusiasts and curious members of the public alike are all encouraged to join Optimi Health in celebrating this important milestone.

“Psychedelics continue to capture the imagination of people looking for hope and better quality of life, specifically those suffering with debilitating mental health conditions,” said Optimi Health CEO, Bill Ciprick. “By having the largest GMP-grade Health Canada licensed mushroom cultivation facility in Canada, we have positioned Optimi to be the number one supplier of safe, natural psilocybin, and we feel good about setting the safest and most stringent production standards in the industry.”

Since being awarded a Dealer's License in February by Health Canada, the Company’s business development team has been focused on securing supply deals and letters of intent with pharmaceutical companies, other licensed suppliers, and drug developers interested in Optimi’s natural GMP-grade product.

In recognition of the importance of community to the success of its facility and all future endeavors, Optimi Founders JJ Wilson, Dane Stevens, and Bryan & Jacob Safarik are inviting the residents of Princeton, British Columbia and the surrounding area to attend alongside Optimi guests and investors.

“As a homegrown, Canadian company founded and built in Princeton, it is our great honour to extend this day of celebration to all residents, our supporters, and anyone else who believes in our ability to produce scalable, natural mushroom formulations for transformational human experiences,” said the Founders. “The entire community of Princeton has played a role in getting Optimi to where it is today, and with that support it’s now our turn to say thank you. So please join us on May 27^th as we open Optimi and Princeton to the world.”

Optimi’s operational footprint includes a 10,000 square foot facility devoted to the production of natural GMP psilocybin for use by approved entities in clinical trials and individuals granted access by Health Canada through legal mechanisms such the Special Access Program and Section 56 exemptions to the Controlled Drugs and Substances Act.

The Company recently announced that it had commenced growing its first crop of natural psilocybin for these purposes, as well as a related partnership with the IMPACT Clinical Trial Accelerator Program housed within Alberta’s Life Sciences Innovation Hub at the University of Calgary.

Those interested in attending this unique event are invited to contact the event organizer, Michael Kydd at:

(902) 880 6121

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health is a homegrown, Canadian success story producing and supplying natural, GMP-grade psilocybin and functional mushrooms that focus on the health and wellness markets. Built with the purpose to produce scalable, natural mushroom formulations for transformational human experiences, our goal is to be the number one trusted, compassionate supplier of safe, natural GMP-grade psilocybin across the world. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.

To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations

Email:

Phone: +1 (902) 880 6121

Web:

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.